Jim Simons
KROS icon

Jim Simons’s Keros Therapeutics KROS Stock Holding History

Jim Simons’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.84M Sell
359,086
-94,396
-21% -$1.05M 0.01% 1604
2026
Q1 		$5.01M Sell
453,482
-138,204
-23% -$2.13M 0.01% 1383
2025
Q4 		$12M Buy
591,686
+436,986
+282% +$7.67M 0.02% 830
2025
Q3 		$2.45M Buy
154,700
+8,100
+6% +$120K ﹤0.01% 1936
2025
Q2 		$1.96M Buy
+146,600
New +$1.98M ﹤0.01% 2126
2024
Q3 		– Sell
-14,300
Closed -$654K – 3725
2024
Q2 		$654K Buy
+14,300
New +$768K ﹤0.01% 2561
2023
Q4 		– Sell
-43,700
Closed -$1.39M – 3940
2023
Q3 		$1.39M Sell
43,700
-24,700
-36% -$922K ﹤0.01% 2088
2023
Q2 		$2.75M Sell
68,400
-52,700
-44% -$2.31M ﹤0.01% 1799
2023
Q1 		$5.17M Buy
121,100
+29,200
+32% +$1.47M 0.01% 1460
2022
Q4 		$4.41M Sell
91,900
-5,300
-5% -$248K 0.01% 1588
2022
Q3 		$3.66M Sell
97,200
-44,500
-31% -$1.54M 0.01% 1634
2022
Q2 		$3.92M Buy
141,700
+136,400
+2,574% +$5.98M ﹤0.01% 1739
2022
Q1 		$288K Buy
+5,300
New +$272K ﹤0.01% 3484
2021
Q4 		– Sell
-24,572
Closed -$972K – 4084
2021
Q3 		$972K Buy
+24,572
New +$874K ﹤0.01% 2567
2021
Q1 		– Sell
-10,100
Closed -$712K – 3530
2020
Q4 		$712K Sell
10,100
-7,600
-43% -$479K ﹤0.01% 2671
2020
Q3 		$683K Buy
17,700
+11,400
+181% +$452K ﹤0.01% 2697
2020
Q2 		$236K Buy
+6,300
New +$194K ﹤0.01% 3117

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Madison Avenue Partners
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Jim Simons's KROS Position: Q2 2026 in Review

Jim Simons reduced its Keros Therapeutics (KROS) stake by 21% in Q2 2026, selling an estimated $1.05M and leaving 359,086 shares worth $3.84M. The position accounts for 0.01% of the portfolio, ranked #1604.

Jim Simons first reported a position in KROS in Q2 2020 and has held it in 17 quarters since. The position peaked at $12M in Q4 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Jim Simons held 359,086 shares of Keros Therapeutics worth $3.84M as of Q2 2026.
  • Jim Simons sold 94,396 Keros Therapeutics shares in Q2 2026, an estimated $1.05M.
  • Keros Therapeutics made up 0.01% of Jim Simons's portfolio in Q2 2026, its #1604 holding.
  • Jim Simons first reported a position in Keros Therapeutics in Q2 2020 and has held it in 17 quarters since.
  • Jim Simons's Keros Therapeutics position peaked at $12M in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.